199 filings
Page 2 of 10
6-K
4xv05tlww4lm5
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
424B3
4u07tdxrl0icdh
12 May 23
Prospectus supplement
9:15am
6-K
rny584dp9r53z9 kajp
12 May 23
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12:00am
EFFECT
uzw6pl77syp
8 May 23
Notice of effectiveness
12:15am
CORRESP
s81d63 6hwox212rx
3 May 23
Correspondence with SEC
12:00am
6-K
uyagbnfyl38jqa fta
30 Mar 23
Current report (foreign)
9:41am
UPLOAD
imo 9zg9i
17 Mar 23
Letter from SEC
12:00am
F-1
v1cd19vb56
10 Mar 23
Registration statement (foreign)
5:25pm
S-8
9itw7gb8hfoz3ic38c
10 Mar 23
Registration of securities for employees
5:21pm
6-K
t59 5h2czptb04s6
1 Mar 23
Current report (foreign)
9:31am
6-K/A
g48cg3dvhlfyk8yd ck
21 Feb 23
Current report (foreign) (amended)
4:30pm
6-K
tc5gr5lka7dsj3deiez
13 Feb 23
Current report (foreign)
12:44pm
6-K
ozzkru
2 Feb 23
Current report (foreign)
6:02am
6-K
ec2m6z5 4k1ib89
31 Jan 23
Current report (foreign)
4:01pm
424B5
4lz0x o5mk
27 Jan 23
Prospectus supplement for primary offering
4:01pm
6-K
v9eudzy9fak8
27 Jan 23
Current report (foreign)
7:15am
6-K
jehbevwrrvtqbtvkec
27 Jan 23
Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product
7:10am
6-K
jwjuq5uhrowz1xyvka
21 Nov 22
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm
6-K
wmt xz9my
3 Oct 22
Sol-Gel Technologies Appoints Michael Glezin Vice
8:05am